BlueBerry Pharma is one of the pharmaceutical organization, which is moving forward successfully in india and maintaining the distinctive portfolio, it is provided under the scientific development team with the greater technology in health care about life protection @ Blueberry Pharmaceuticals
Velasof is an anti-hepatitis C viral medicine, containing active components known as Sofosbuvir and Velpatasvir available in the strength of 400mg & 100mg respectively. Velpatasvir is a class of anti-hepatitis C viral drug, called NS5A multiplication complex inhibitors. This may have combined with other anti-viral agent Sofosbuvir which expels its work by stopping the virus which may causes hepatitis C viral infection from spreading inside the body. Velasof tablet is not a curable; it is only used to control the spreading of disease.
Velasof tablet
VELASOF INDICATION AND USAGE
Velasof tablets are used only in adult’s patients with long lasting hepatitis C virus caused by genotypes I, II, III, IV, V or VI In two conditions Velasof tablets are used;
Without cirrhosis or with compensated cirrhosis (child Pugh A or B) With decompensated cirrhosis by combining with ribavirin (child Pugh C)
VELASOF MECHANISM OF ACTION
Both the components in Velasof tablets are involved in inhibiting nonstructural protein which is essential for viral multiplication. Sofosbuvir is a NS5B inhibitor, whereas Velpatasvir is considered as NS5Ainhibitor Velasof is a directly acting anti-hepatitis C viral agent.
Sofosbuvir leads to produce pharmacologically active uridine analog triphosphate by intracellular metabolism. Sofosbuvir is inserted into viral HCV DNA by NS5B polymerase and act as a chain terminator. Velpatasvir inhibits NS5A protein which is responsible for viral assembly.
VELASOF UNDERGOES ADME PROPERTY
The peak plasma concentration time of Sofosbuvir and Velpatasvir is 0.5 to 1 hour and 3 hours respectively. The effect of food with Velasof tablet determines as; With moderate meal: Sofosbuvir increases to 60%; increases to 34% With high fat meal: Sofosbuvir increases to 78%; increases to 21% The blood plasma ratio of Sofosbuvir & Velpatasvir is 0.7 & 0.52 to 0.67 respectively
The human plasma protein bound; Sofosbuvir & Velpatasvir is 61 to 65% &>99.5% respectively. The metabolism of Sovihep occurs; Sofosbuvir: cathepsin A, or carboxyl esterase Velpatasvir: CYP2B6, CYP2C8 or CYP3A4
The elimination of Velasof occurs via; Sofosbuvir: Glomerular filtration, active tubular secretion Velpatasvir: biliary excretion The terminal half-life of Velasof tablets; Sofosbuvir: 0.5 hours; GS331007: 25 hours & Velpatasvir 15 hours Elimination of Sofosbuvir in urine at 80%; feces at 14% Elimination of Velpatasvir in urine 0.4%; feces at 94%
VELASOF CAUSES UNDESIRABLE EFFECTS
Headache, Fatigue, Nausea, Asthenia, Insomnia, Anemia, HBV reactivation, Elevation of lipase & amylase levels, Elevation of creatine kinase, Cardiac disorder like bradycardia while concomitant with amiodarone, Angioedema, Skin rashes
VELASOF PRECAUTIONS
Exposure of hepatitis B viral infection occurs in HBV/HCV co infections Serious symptomatic bradycardia while concomitant with amiodarone Risk of depletion of therapeutic effect occurs due to combination of Velasof with P-gp inducers or CYP3A4 inducers.
Fetal adverse occurs while concomitant with ribavirin For all these conditions, withhold or discontinue the therapy with Velasof tablets.
Comments
Post a Comment